Aptose Biosciences Inc.
APS.TO
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 86.74% | 39.26% | 48.67% | 29.51% | -19.55% |
| Total Depreciation and Amortization | -11.82% | -13.51% | -10.53% | -16.79% | 10.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -222.24% | -99.65% | -63.67% | -55.24% | -33.78% |
| Change in Net Operating Assets | -384.97% | -1,678.92% | 443.53% | -971.95% | 311.79% |
| Cash from Operations | 12.95% | 1.52% | 57.21% | -4.08% | -7.03% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | 203.16% | 32.70% | -88.97% |
| Cash from Investing | -100.00% | -- | 202.50% | 32.74% | -88.97% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 103.95% | 344.63% | 23,594.00% | 1,554.90% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 1,460.00% | -- | -3,440.00% | -- | -- |
| Cash from Financing | 696.84% | 104.16% | 330.62% | 23,594.00% | 1,574.51% |
| Foreign Exchange rate Adjustments | -- | -- | 66.67% | -75.00% | -116.67% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 80.60% | -105.03% | 106.85% | 86.59% | -172.03% |